A study focused on whether STAS could be a useful add'l histologic descriptor to supplement existing ones of VPI & LVI. Data supports the recommendation to include STAS as a histologic descriptor for the 9th Edition of the TNM Classification of #lungcancer .bit.ly/3IZkx3x

Last Call! The last day to apply for the #IASLC #Reviewer Workshop is Monday, April 1. Join us at #WCLC24 for this one-day workshop for early and mid-career IASLC members. Open to members in the Americas. Apply Now at: iaslc.org/reviewer-works… #LCSM

Controversies in #LungCancer : Here are the reasons why some researchers and clinicians believe that the combination of chemotherapy and osimertinib should not be the first-line treatment for all advanced #EGFR + #NSCLC . bit.ly/4cAElI2 #LCSM

Controversies in #LungCancer : Read why some researchers and clinicians believe that the combination of chemotherapy and osimertinib should be the first-line treatment for all advanced #EGFR + #NSCLC . bit.ly/3vsDNU8 #LCSM

The authors describe the current landscape of pertinent clinical trials focusing on MET-targeted strategies and discuss future developmental directions in this rapidly expanding field. Read the review here: bit.ly/3IQFttt #LCSM

A first retrospective study to comprehensively characterize the genomic landscape of #NSCLC in Ireland, which has a higher prevalence of pts w/KRAS-mt NSCLC & a lower prevalence of ALK, ROS1 & RET fusion-positive NSCLC, compared w/similar data sets. bit.ly/3vrWU0w #LCSM

The Japanese prospective nationwide registry study on CIRT, which began in 2016, studied real-world clinical outcomes of CIRT for operable pts w/stage I #NSCLC . The authors found that this treatment method has favorable outcomes w/tolerable toxicity. bit.ly/4aqaNLk #LCSM

In the phase 3 RATIONALE-312 study, researchers evaluated efficacy & safety of tislelizumab + chemo as first-line treatment for ES-SCLC. This treatment demonstrated statistically significant clinical benefit & manageable safety compared to placebo + chemo. bit.ly/4akAXPN

The detection of tumor DNA in the supernatant of guide sheath flush fluid collected during r-EBUS bronchoscopy represents a sensitive & complementary method for genotyping #NSCLC , theoretically reducing the false-negative rate of DNA genotyping from plasma.bit.ly/3xcvrjO

The #Lung Cancer Worldwide series continues with Switzerland. Read more to learn the epidemiology, treatment, and the potential future of screening in Switzerland. bit.ly/3vaHsG8 #LCSM

Reminder! The last day to apply for the #IASLC #Reviewer Workshop is Monday, April 1. Join us at #WCLC24 for this one-day workshop for early and mid-career IASLC members. Open to members in the Americas. Apply at
iaslc.org/reviewer-works… JTO & JTO CRR #LCSM

This study analyzed all metastatic categories of the TNM classification of #NSCLC to propose modifications of the M component in the 9th edition, the data validates the 8th edition M1a & M1b categories. Read more including a proposal re: the M1c category: bit.ly/3IrQamc

To provide a more detailed analysis of TKIs' impact on pts w/EGFRmut #NSCLC , authors found that pts w/TP53mut/TSGmut tumors have an aggressive disease phenotype & inferior outcomes on EGFR TKIs, implying that some pts would benefit from add. therapy types. bit.ly/3Q6o8jr

The cutoff for sensitive/refractory #SCLC is not derived from rigorous analytical method. Its applicability remains uncertain in the Chemo-ICI era. Authors M. Torasawa | Medical Oncologist🫁, Hidehito HORINOUCHI, et al. set out to clarify & reassure the cutoff in this study. bit.ly/3T4zOG9 #LCSM

We are delighted to announce that articles published in #JTOCRR are now indexed on Web of Science. First Journal Impact Factor is expected in June 2024! Read all articles here: jtocrr.org #IASLC #openaccess

This month's editor's choice revisits this study, which investigates the association between RA and the risk of lung cancer. Patients with RA showed an increased risk of lung cancer compared to the group without RA. Read more here: bit.ly/4060NTz #LCSM

In this study (LEAP-007), the authors found that first-line #lenvatinib w/ #pembrolizumab in #NSCLC w/PD-L1 TPS ≥1% had an unfavorable benefit‒risk ratio & met the futility criterion for OS. Read more about the study here: bit.ly/3SSiRPn #LCSM

In seeking optimal consolidation therapy for pts w/EGFRmut stage III #NSCLC , this study suggests that pts w/stage III unresectable NSCLC w/a sensitizing EGFR mutation, consolidation #osimertinib was associated w/longer rwPFS than durvalumab or observation. bit.ly/3OD0oUq

The study aimed to prospectively investigate the bidirectional association between CVD and LC, and whether this association differs across genetic risk levels. Findings show that there is such an association, though further clinical studies are required. bit.ly/49oeuAQ

This article details a systematic analysis of MATE-1 inhibitor (MATEi)-treated patients to comprehensively characterize the phenomenon in which MATE-1 is also blocked by TKIs causing creatinine to be retained in the serum. Read more about the findings here.bit.ly/3OzNuq0